The Myeloid Genomics Testing and Precision Assay is designed to offer faster, more precise insights into cancer and myeloid disorders

Agilus Diagnostics announced a ground-breaking achievement in genomic testing with its industry-leading 3-day turnaround time (TAT) for test results in myeloid malignancies.

Next Generation Sequencing (NGS) is revolutionising genetic testing by enabling precise, comprehensive analysis of genetic variations, empowering clinicians with actionable insights for personalised patient care. While genomic testing has traditionally been a lengthy process, often taking weeks to deliver results, Agilus Diagnostics has set a new benchmark by delivering individualised reports—meticulously crafted by expert molecular pathologists—in just three days (for myeloid malignancies). This rapid turnaround ensures faster clinical decision-making, ultimately improving patient outcomes and setting us apart as leaders in precision diagnostics.

The Myeloid Genomics Testing and Precision Assay is designed to offer faster, more precise insights into cancer and myeloid disorders. The Myeloid Genomics Testing covers 79 genes, including those linked to inherited risks, to detect key genetic changes like mutations and fusions. This enables personalized treatment recommendations for conditions like Acute Myeloid Leukemia (AML) and Myeloproliferative Neoplasms (MPN). Reports are reviewed by expert pathologists and include internationally recognized risk assessment tools and therapy suggestions tailored to the patient.

The Genomic Profiling Precision Assay provides comprehensive genomic profiling for cancers like lung, colon, breast, and melanoma by analyzing 50 critical genes. It identifies mutations, amplifications, and fusion genes, offering actionable insights for targeted treatments. With optimized panels for tissue and blood samples, the test ensures accurate results within two days for liquid biopsy samples and seven days for tissue block samples, making it a powerful tool for precision medicine.

“Our three-day genomic testing initiative for myeloid malignancies addresses one of the biggest challenges in precision oncology —Time. With this breakthrough, Agilus Diagnostics is not only setting a new industry standard but also transforming patient care by enabling faster diagnoses and treatment,” said Dr Anand K, MD and CEO, Agilus Diagnostics.